Simvastatin Hydroxy Acid Fails to Attain Sufficient Central Nervous System Tumor Exposure to Achieve a Cytotoxic Effect: Results of a Preclinical Cerebral Microdialysis Study

Drug Metabolism and Disposition : the Biological Fate of Chemicals
Y T PatelClinton F Stewart

Abstract

3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors were potent hits against a mouse ependymoma cell line, but their effectiveness against central nervous system tumors will depend on their ability to cross the blood-brain barrier and attain a sufficient exposure at the tumor. Among 3-hydroxy-3-methylglutaryl coenzyme A inhibitors that had activity in vitro, we prioritized simvastatin (SV) as the lead compound for preclinical pharmacokinetic studies based on its potential for central nervous system penetration as determined from in silico models. Furthermore, we performed systemic plasma disposition and cerebral microdialysis studies of SV (100 mg/kg, p.o.) in a murine model of ependymoma to characterize plasma and tumor extracellular fluid (tECF) pharmacokinetic properties. The murine dosage of SV (100 mg/kg, p.o.) was equivalent to the maximum tolerated dose in patients (7.5 mg/kg, p.o.) based on equivalent plasma exposure of simvastatin acid (SVA) between the two species. SV is rapidly metabolized in murine plasma with 15 times lower exposure compared with human plasma. SVA exposure in tECF was <33.8 ± 11.9 µg/l per hour, whereas the tumor to plasma partition coefficient of SVA was <0.084 ± 0.008. Compared with in vit...Continue Reading

References

Nov 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·P J CaseyJ E Buss
Jul 6, 2000·International Journal of Pharmaceutics·M FeherJ M Schmidt
Sep 10, 2003·Neurosurgical Review·Jan GliemrothA Jorge A Terzis
Nov 12, 2005·The Journal of Pharmacology and Experimental Therapeutics·Karin M ThelenDieter Lütjohann
Feb 21, 2006·NeuroRx : the Journal of the American Society for Experimental NeuroTherapeutics·Hassan Pajouhesh, George R Lenz
Mar 22, 2006·The Oncologist·Katja HindlerCharles D Collard
Jun 23, 2007·Nature Reviews. Drug Discovery·Panagiotis A KonstantinopoulosAthanasios G Papavassiliou
Dec 9, 2008·Journal of Neurosurgery·Courtney S McGuirePaul G Fisher
Mar 11, 2009·The Lancet Oncology·Thomas E MerchantRobert A Sanford
May 2, 2009·Journal of Pharmaceutical Sciences·Jurgen MenschPatrick Augustijns
Nov 23, 2011·Pharmacological Reviews·Patrizia GazzerroMaurizio Bifulco
Jul 27, 2012·Journal of Pharmaceutical Sciences·Fatma Goksin BaharTeruko Imai
Oct 29, 2013·Cancer Chemotherapy and Pharmacology·Tamer A AhmedMarkos Leggas
Nov 26, 2013·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·M O JacusC F Stewart
Feb 12, 2015·Clinical Pharmacology and Therapeutics·K E ParrishW F Elmquist
Jun 16, 2015·Nature Genetics·Kumarasamypet M MohankumarRichard J Gilbertson

❮ Previous
Next ❯

Citations

May 6, 2020·International Journal of Molecular Sciences·Ehsan SamieiMohsen Akbari

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Brain Barrier

The blood brain barrier is a border that separates blood from cerebrospinal fluid. Discover the latest search on this highly selective semipermeable membrane here.

Cancer Metabolism

In order for cancer cells to maintain rapid, uncontrolled cell proliferation, they must acquire a source of energy. Cancer cells acquire metabolic energy from their surrounding environment and utilize the host cell nutrients to do so. Here is the latest research on cancer metabolism.

Blood Brain Barrier Chips

The blood brain barrier (BBB) is comprised of endothelial cells that regulate the influx and outflux of plasma concentrations. Lab-on-a-chip devices allow scientists to model diseases and mechanisms such as the passage of therapeutic antibodies across the BBB. Discover the latest research on BBB chips here.

Blood Brain Barrier Regulation in Health & Disease

The blood brain barrier is essential in regulating the movement of molecules and substances in and out of the brain. Disruption to the blood brain barrier and changes in permeability allow pathogens and inflammatory molecules to cross the barrier and may play a part in the pathogenesis of neurodegenerative disorders. Here is the latest research in this field.

Related Papers

European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences
M O JacusClinton F Stewart
Der Internist
J Thiery, D Seidel
Nihon rinsho. Japanese journal of clinical medicine
A Endo
Natural Product Reports
A Endo, K Hasumi
© 2022 Meta ULC. All rights reserved